Prostate Cancer Coverage from Every Angle


Precision Radiation Technique for Prostate Cancer May Reduce Short-Term Toxicity
Beyond Brachytherapy: Does Adding EBRT Benefit Those With Intermediate-Risk Prostate Cancer?
Researchers Link Metabolic Biomarkers With Increased Risk of Prostate Cancer in Black Men
Prostate Cancer Prognosis in Asian Versus White Men
Predicting Recurrence of Prostate Cancer With PSMA PET Imaging
ASCOBT 2023: Can Exercise Improve Quality of Life in Patients on Androgen-Deprivation Therapy?
Patient Point of View: The Monetary Impact of Treatment for Metastatic Prostate Cancer
ASCOBT 2023: Radiomic Model May Improve the Ability to Predict Prostate Cancer Recurrence
ASCOBT 2023: Interplay of DNA Damage Response Variants and the Transcriptome in East Asian Patients With Prostate Cancer
ASCOBT 2023: Can Exercise and Psychotherapy Improve Sexual Health in Patients With Prostate Cancer?
FDA Approves Niraparib Combination Therapy for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
ASCOBT 2023: Clinical Implications of Dosimetric Feasibility Study of Radiotherapy for Prostate Cancer
Using Artificial Intelligence to Map Cancer in the Prostate
Can a New Target in Prostate Cancer Unlock Better Outcomes Across Cancer Types?
Diagnostic and Treatment Disparities Among Hispanic Men With Metastatic Prostate Cancer
Primary Survival Analysis of ENZAMET: Role of Enzalutamide in Testosterone Suppression in Prostate Cancer
Comparing the Effect of Darolutamide Versus Enzalutamide on Post-Treatment Testosterone Levels
Safety Data From TALAPRO-2 Trial of Talazoparib Plus Enzalutamide in Metastatic Prostate Cancer
Health-Related Quality of Life Data From PROpel on Abiraterone Plus Olaparib in Prostate Cancer
New Angles Explored for Treating High-Volume Metastatic Castration-Sensitive Prostate Cancer
Using Genetically Adjusted PSA Levels to Improve Prostate Cancer Screening
Should Enzalutamide and Abiraterone Be Combined in Conjunction With Long-Term Androgen-Deprivation Therapy?
ASCO 2023: Real-World Comparison of Darolutamide, Enzalutamide, and Apalutamide in Nonmetastatic Prostate Cancer
ASCO 2023: Can Nutritional Programs Mitigate Nutritional Risks of Androgen-Deprivation Therapy for Prostate Cancer?
ASCO 2023: Traditional Genetic Counseling Versus Patient-Driven Web Tools for Prostate Cancer Germline Testing
ASCO 2023: Does PSA Nadir After Radiotherapy Impact Outcomes in Localized Prostate Cancer?
FDA Approves Talazoparib With Enzalutamide for HRR-Mutated Metastatic Prostate Cancer
ASCO 2023: Impact of Irradiation in Low-Volume Metastatic Prostate Cancer
ASCO 2023: Black and White Patients Fared Differently When Treated With Combination Therapy for Prostate Cancer
ASCO 2023: Can HRR Gene Alterations Predict Prognosis in Metastatic Castration-Resistant Prostate Cancer?
ASCO 2023: AI-Based Biomarker and Response to Long-Term Androgen-Deprivation Therapy
ASCO 2023: TALAPRO-2 Update of Talazoparib Plus Enzalutamide in Metastatic Prostate Cancer With HRR Gene Alterations
ASCO 2023: Early-Phase Trial of Radionuclide Therapy Plus Olaparib in Metastatic Prostate Cancer
FDA Approves Olaparib-Based Combination for BRCA-Mutated Metastatic Prostate Cancer
FDA Approves First Radiohybrid PSMA-Targeted PET Imaging Agent for Prostate Cancer
Are Older Men Being Overscreened for Prostate Cancer? California Survey Results Suggest Yes
AUA 2023: Update on Novel Radioligand Therapy for Castration-Resistant Prostate Cancer
AUA 2023: Patients’ Preferences Take Center Stage in Study of Androgen-Deprivation Therapy
AUA 2023: ARAMIS Trial Update on Darolutamide in Nonmetastatic Castration-Resistant Prostate Cancer
Transgender Women May Be at Risk for Prostate Cancer, Study Reveals
AUA 2023: Disparities Among Survivorship Programs for Genitourinary Cancer
$1.7M Grant for Novel Prostate Cancer Treatment Awarded to Sanford-Burnham Researcher
AUA 2023: Risk of Cardiovascular Events After Androgen-Deprivation Therapy for Prostate Cancer
AUA 2023: How Does AI Model Compare With Radiologists in Detecting Prostate Cancer on MRI?
AACR 2023: Darolutamide-Based Combination Therapy for Metastatic Castration-Resistant Prostate Cancer
AACR 2023: Does Inflammation Tie Together Prostate Cancer, Colorectal Cancer, and Ulcerative Colitis?
AACR 2023: Researchers Focus on Solving the Enzalutamide Efficacy Puzzle in Prostate Cancer
Phase II EXTEND Trial: Metastasis-Directed Therapy for Advanced Prostate Cancer
Novel Monoclonal Antibody Shows Activity in High-Risk Prostate Cancers
AACR 2023: Novel Targeted Combination Therapy for Metastatic Castration-Resistant Prostate Cancer
NCCN 2023: Case-Based Presentation Features Updates on Managing Metastatic Prostate Cancer
AACR 2023: Prostate Cancer Mortality Disparities in Men of African Ancestry Living in Florida
AACR 2023: Racial Disparity in Outcomes After Prostatectomy
Is Nadir PSA Value an Independent Predictor of Survival in Prostate Cancer?
Screening for Colorectal Cancer Among Prostate Cancer Survivors: Focus on Physical and Mental Health
Can Darolutamide Improve Outcomes in High-Risk Prostate Cancer? Researchers Intend to Find Out
Darolutamide Plus Testosterone Cypionate in 'Extreme Bipolar Androgen Therapy' for Prostate Cancer

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.